Cargando…
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893928/ https://www.ncbi.nlm.nih.gov/pubmed/35303626 http://dx.doi.org/10.1016/j.leukres.2022.106819 |
| _version_ | 1784662522839695360 |
|---|---|
| author | Auteri, Giuseppe Bartoletti, Daniela Di Pietro, Christian Sutto, Emanuele Mazzoni, Camilla Romagnoli, Andrea Davide Vianelli, Nicola Lazzarotto, Tiziana Cavo, Michele Palandri, Francesca |
| author_facet | Auteri, Giuseppe Bartoletti, Daniela Di Pietro, Christian Sutto, Emanuele Mazzoni, Camilla Romagnoli, Andrea Davide Vianelli, Nicola Lazzarotto, Tiziana Cavo, Michele Palandri, Francesca |
| author_sort | Auteri, Giuseppe |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8893928 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88939282022-03-04 Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity Auteri, Giuseppe Bartoletti, Daniela Di Pietro, Christian Sutto, Emanuele Mazzoni, Camilla Romagnoli, Andrea Davide Vianelli, Nicola Lazzarotto, Tiziana Cavo, Michele Palandri, Francesca Leuk Res Correspondence Elsevier Ltd. 2022-05 2022-03-03 /pmc/articles/PMC8893928/ /pubmed/35303626 http://dx.doi.org/10.1016/j.leukres.2022.106819 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Auteri, Giuseppe Bartoletti, Daniela Di Pietro, Christian Sutto, Emanuele Mazzoni, Camilla Romagnoli, Andrea Davide Vianelli, Nicola Lazzarotto, Tiziana Cavo, Michele Palandri, Francesca Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity |
| title | Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity |
| title_full | Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity |
| title_fullStr | Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity |
| title_full_unstemmed | Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity |
| title_short | Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity |
| title_sort | longer-term response to sars-cov-2 vaccine in mpn patients: role of ruxolitinib and disease severity |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893928/ https://www.ncbi.nlm.nih.gov/pubmed/35303626 http://dx.doi.org/10.1016/j.leukres.2022.106819 |
| work_keys_str_mv | AT auterigiuseppe longertermresponsetosarscov2vaccineinmpnpatientsroleofruxolitinibanddiseaseseverity AT bartolettidaniela longertermresponsetosarscov2vaccineinmpnpatientsroleofruxolitinibanddiseaseseverity AT dipietrochristian longertermresponsetosarscov2vaccineinmpnpatientsroleofruxolitinibanddiseaseseverity AT suttoemanuele longertermresponsetosarscov2vaccineinmpnpatientsroleofruxolitinibanddiseaseseverity AT mazzonicamilla longertermresponsetosarscov2vaccineinmpnpatientsroleofruxolitinibanddiseaseseverity AT romagnoliandreadavide longertermresponsetosarscov2vaccineinmpnpatientsroleofruxolitinibanddiseaseseverity AT vianellinicola longertermresponsetosarscov2vaccineinmpnpatientsroleofruxolitinibanddiseaseseverity AT lazzarottotiziana longertermresponsetosarscov2vaccineinmpnpatientsroleofruxolitinibanddiseaseseverity AT cavomichele longertermresponsetosarscov2vaccineinmpnpatientsroleofruxolitinibanddiseaseseverity AT palandrifrancesca longertermresponsetosarscov2vaccineinmpnpatientsroleofruxolitinibanddiseaseseverity |